JPMorgan Chase & Co. Lowers Ardent Health (NYSE:ARDT) Price Target to $11.00

Ardent Health (NYSE:ARDT) had its target price cut by equities researchers at JPMorgan Chase & Co. from $12.00 to $11.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 28.21% from the company’s current price.

A number of other analysts have also weighed in on the company. Weiss Ratings restated a “sell (d)” rating on shares of Ardent Health in a research note on Monday, December 29th. Wall Street Zen cut shares of Ardent Health from a “buy” rating to a “hold” rating in a research report on Sunday, November 23rd. KeyCorp cut shares of Ardent Health from an “overweight” rating to a “sector weight” rating in a research note on Monday, November 17th. Stephens lowered their price target on shares of Ardent Health from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Friday, November 14th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price objective (down previously from $22.00) on shares of Ardent Health in a report on Friday, November 14th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Ardent Health presently has an average rating of “Hold” and an average target price of $14.58.

Ardent Health Price Performance

ARDT stock traded down $0.02 during trading on Tuesday, hitting $8.58. 31,258 shares of the stock traded hands, compared to its average volume of 341,313. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of 5.92, a P/E/G ratio of 4.91 and a beta of 0.72. Ardent Health has a one year low of $8.28 and a one year high of $15.65. The company has a current ratio of 2.08, a quick ratio of 1.95 and a debt-to-equity ratio of 0.67. The company has a 50 day simple moving average of $9.08 and a 200 day simple moving average of $11.69.

Ardent Health (NYSE:ARDT) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.10. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.55 billion. Ardent Health had a net margin of 3.24% and a return on equity of 19.02%. Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. Equities analysts expect that Ardent Health will post 1.23 EPS for the current fiscal year.

Institutional Trading of Ardent Health

A number of hedge funds have recently modified their holdings of the company. CWM LLC increased its stake in Ardent Health by 990.6% in the second quarter. CWM LLC now owns 2,203 shares of the company’s stock valued at $30,000 after purchasing an additional 2,001 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Ardent Health during the 3rd quarter worth $61,000. KLP Kapitalforvaltning AS bought a new position in Ardent Health during the third quarter worth about $80,000. New York State Common Retirement Fund lifted its holdings in Ardent Health by 121.4% during the second quarter. New York State Common Retirement Fund now owns 6,200 shares of the company’s stock worth $85,000 after acquiring an additional 3,400 shares in the last quarter. Finally, State of Alaska Department of Revenue bought a new stake in shares of Ardent Health in the third quarter worth about $103,000.

More Ardent Health News

Here are the key news stories impacting Ardent Health this week:

• Positive Sentiment: One bullish take surfaced summarizing a “bull case” thesis arguing Ardent’s valuation looks attractive on trailing/forward P/E metrics and that upside exists if operational issues are resolved. Ardent Health, Inc. (ARDT): A Bull Case Theory
• Neutral Sentiment: Brokerage consensus remains a “Hold”, reflecting mixed views on near-term fundamentals versus longer-term valuation and execution risks. Ardent Health, Inc. (NYSE:ARDT) Given Consensus Recommendation of “Hold” by Brokerages
• Negative Sentiment: A cluster of law firms has filed or announced investigations and class actions alleging that Ardent misled investors about its revenue-recognition processes and adequacy of professional liability reserves; multiple firms are soliciting lead plaintiffs and highlighting a share plunge tied to the Q3 2025 results. These suits raise the risk of litigation costs, potential restatements or reserve adjustments, and continued share-price volatility. Sources: Hagens Berman, Bleichmar Fonti & Auld (BFA), Rosen Law, Hagens Berman (PRNews), Wolf Haldenstein, Faruqi & Faruqi, and Bronstein, Gewirtz & Grossman.
  ARDT INVESTOR NOTICE: Ardent Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
  ARDT CLASS ACTION: Did Ardent Health, Inc. Mislead Investors? BFA Law Notifies Investors
  ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ardent Health, Inc. Investors to Secure Counsel
  ARDT INVESTOR ALERT: Ardent Health, Inc. Investors with Substantial Losses Have Opportunity to Lead
  Shareholders who lost money in shares of Ardent, Inc. (NYSE: ARDT) Should Contact Wolf Haldenstein
  SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims
  Bronstein, Gewirtz & Grossman LLC Urges Ardent Health, Inc. Investors to Act

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.